多中心量化1476例前列腺动脉栓塞术的辐射暴露及相关风险
这项回顾性多中心研究纳入2014年1月至2021年5月在10个国际高容量中心接受前列腺动脉栓塞术的1476例患者,量化辐射剂量并评估辐射相关不良事件。固定介入单元的中位有效剂量为17.8 mSv,移动单元为12.3 mSv;未报告辐射相关90天不良事件。
要点
- 固定介入单元中位有效剂量17.8 mSv,移动单元12.3 mSv。
- 有射线不透性植入物者中位累积空气比释动能高于无植入物者。
- 未报告辐射相关90天不良事件。
核心结论
- 接受前列腺动脉栓塞术的患者在固定介入或移动透视单元下暴露的中位有效辐射剂量分别为17.8 mSv或12.3 mSv,未报告90天辐射相关不良事件。
研究设计与样本
- 回顾性研究,纳入2014年1月至2021年5月在10个国际高容量中心由经验丰富操作者实施前列腺动脉栓塞术的任何适应症患者1476例。
诊断标准与关键数值
- 中位手术有效剂量固定介入单元17.8 mSv,移动单元12.3 mSv;累积空气比释动能和有效剂量均与体重指数正相关(R2=0.15和0.17;P<.001),与透视时间正相关(R2=0.16和0.08;P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Prostatic artery embolization (PAE) is a safe, minimally invasive angiographic procedure that effectively treats benign prostatic hyperplasia; however, PAE-related patient radiation exposure and associated risks are not completely understood. Purpose To quantify radiation dose and assess radiation-related adverse events in patients who underwent PAE at multiple centers. Materials and Methods This retrospective study included patients undergoing PAE for any indication performed by experienced operators at 10 high-volume international centers from January 2014 to May 2021. Patient characteristics, procedural and radiation dose data, and radiation-related adverse events were collected. Procedural radiation effective doses were calculated by multiplying kerma-area product values by an established conversion factor for abdominopelvic fluoroscopy-guided procedures. Relationships between cumulative air kerma (CAK) or effective dose and patient body mass index (BMI), fluoroscopy time, or radiation field area were assessed with linear regression. Differences in radiation dose stemming from radiopaque prostheses or fluoroscopy unit type were assessed using two-sample t tests and Wilcoxon rank sum tests. Results A total of 1476 patients (mean age, 69.9 years ± 9.0 [SD]) were included, of whom 1345 (91.1%) and 131 (8.9%) underwent the procedure with fixed interventional or mobile fluoroscopy units, respectively. Median procedure effective dose was 17.8 mSv for fixed interventional units and 12.3 mSv for mobile units. CAK and effective dose both correlated positively with BMI (R2 = 0.15 and 0.17; P < .001) and fluoroscopy time (R2 = 0.16 and 0.08; P < .001). No radiation-related 90-day adverse events were reported. Patients with radiopaque implants versus those without implants had higher median CAK (1452 mGy [range, 900-2685 mGy] vs 1177 mGy [range, 700-1959 mGy], respectively; P = .01). Median effective dose was lower for mobile than for fixed interventional systems (12.3 mSv [range, 8.5-22.0 mSv] vs 20.4 mSv [range, 13.8-30.6 mSv], respectively; P < .001). Conclusion Patients who underwent PAE performed with fixed interventional or mobile fluoroscopy units were exposed to a median effective radiation dose of 17.8 mSv or 12.3 mSv, respectively. No radiation-related adverse events at 90 days were reported. © RSNA, 2024 See also the editorial by Mahesh in this issue.
引用
- Ayyagari R, Rahman SZ, Grizzard K, et al. Multicenter Quantification of Radiation Exposure and Associated Risks for Prostatic Artery Embolization in 1476 Patients. Radiology. 2024. PMID: 38441098. doi:10.1148/radiol.231877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。